IGF-1 LR3 research protocols: engineered to evade its own binding proteins

Insulin-like growth factor 1 circulates almost entirely bound. Roughly 98 percent of endogenous IGF-1 is captured by IGF binding proteins, principally IGFBP-3 in a ternary complex with the acid-labile subunit. That binding is not an inconvenience of measurement, it is the regulatory system: bound IGF-1 is inactive and protected, and release from the complex governs when and where the growth factor acts.

What LR3 modifies, and why

IGF-1 LR3, Long R3 IGF-1, carries two engineered changes to the native 70-residue sequence:

• Arg3 substitution. Glutamic acid at position 3 is replaced with arginine. This single substitution dramatically reduces affinity for the IGF binding proteins, so the molecule largely escapes capture.
• 13-residue N-terminal extension. An additional peptide sequence at the N-terminus further reduces binding protein affinity and increases stability.

The combined result is a molecule with substantially extended circulating half-life relative to native IGF-1, reported in hours rather than the roughly 10 to 20 minutes of free native IGF-1. It retains affinity for the IGF-1 receptor itself, so receptor-level pharmacology is broadly preserved while the binding protein regulatory layer is bypassed.

Why a 1 mg vial is the standard unit

Every other compound in this catalogue ships in 5 to 50 mg vials. IGF-1 LR3 ships as 1 mg, and the reason is potency combined with cost. As a 70-residue recombinant protein it is expensive to produce, and published work uses it at concentrations far below those typical for short peptides. A 1 mg vial reconstituted to 1 mL yields 1 mg/mL, from which working dilutions in the nanogram to microgram per mL range are prepared.

Handling: this one is genuinely fragile

A 70-residue protein with three disulfide bonds and defined tertiary structure behaves nothing like a 5-residue peptide. Four rules that matter more here than anywhere else in the catalogue:

1. Never vortex or shake. Shear and air-liquid interface exposure denature structured proteins. Swirl gently, and accept slow dissolution.
2. Aliquot at first reconstitution, without exception. Published stability figures for structured proteins cluster around 5 to 10 percent activity loss per freeze-thaw cycle. Three cycles is a meaningful fraction of your material.
3. Some protocols specify a dilute acetic acid solvent rather than bacteriostatic water, because IGF-1 solubility improves at mildly acidic pH. Follow the solvent your assay was validated with; our carrier solvent guide covers the tradeoffs.
4. Avoid repeated warming. Return aliquots to minus 20 or minus 80 degrees Celsius promptly.

Relationship to growth hormone research

Hepatic IGF-1 production is the principal downstream mediator of growth hormone action, which is why IGF-1 appears constantly in growth-axis literature alongside GHRH analogues and secretagogues. A model treated with CJC-1295 or ipamorelin is being studied partly through its IGF-1 response. Administering IGF-1 LR3 directly bypasses the entire GH axis and interrogates receptor-level signalling in isolation. Those are different experiments, and conflating them is a common misreading. See our IGF-1 LR3 mechanism overview for the muscle literature specifically.

Sourcing and verification

Purity determines whether a result is reproducible. Every Lumera Labs lot ships with a lot-specific certificate of analysis reporting HPLC-UV purity, and those certificates are published at Lab Results before you order rather than emailed afterward. Orders ship from within Canada in 24 to 48 hours, free over $200 CAD, which removes customs exposure and keeps transit short for temperature-sensitive material.

FAQ